This section is published monthly to inform the practicing physician about new drug products and medical equipment made avail- able on the market. It is a reference section prepared by THE JOURNAL, from descriptive material furnished by ethical manufac- turers. The American Osteopathic Association does not necessarily advocate the use of these products nor disapprove any product not included. The purpose of the section is to provide trustworthy information in a convenient form.

Product News

Pharmacodynamics • Compared therapy are reported to be ex- with ferrous sulfate, Ferronord tremely rare with Ferronord-DLA. provides a more readily absorbed, Iron toxicity is likely to be encoun- fully utilized, and safely tolerated tered only with massive over- form of iron. The complex bond dosage. with amino acid protects the fer- rous iron from oxidation into in- Indications • Ferronord-DLA is OM bAY- LONG soluble and irritating compounds. indicated for the treatment of all :erronord:ol The amino acid component in- the common iron deficiency ane- C:11 leS creases absorption through the in- mias, including the hypochromic

rrof frootmont of iroft testinal mucosa, so that absorption anemia of pregnancy. 4.1kienty orowniat, of Ferronord is 5 times that of fer- rEit.TINSI El I AHIIIIATIY110.° / DO. rous sulfate. In the prolonged- Contraindications • There are no action form. the clinical advantages specific contraindications to the of Ferronord are enhanced because use of Ferronord-DLA in the pre- more iron is allowed to reach the scribed manner. small intestine, the site of optimal FERRONORD®-DLA CAPSULES absorption. During therapy with Dosage schedule • For adults the Ferronord-DLA, serum iron is ele- usual dose is one capsule each Chemistry • Ferronord is a brand vated within 3 hours, reticulocyte morning; in severe anemia a cap- of ferroglycine sulfate complex, an response is at a peak within 5 days, sule may be taken twice a day. equimolecular, chelated complex and hemoglobin levels are sharply Children receive the same dosage of ferrous sulfate and the amino increased within 3 weeks. Clinical in most cases. The capsules can be acid, glycine. The chelate bonding studies indicate that Ferronord- taken between meals. is such as to permit the ferrous DLA can be administered safely to iron to be released readily. In pregnant patients, those with gas- How • supplied • Ferronord-DLA Ferronord-DLA the pure hydrated trointestinal disorders, and in many capsules are available in bottles complex has been incorporated into cases those who have been intoler- of 30. prolonged-action granules formu- ant of other iron therapy. lated to provide 8 hours of thera- Manufacturer • Cooper, Tinsley peutic effect in cases of iron de- Toxicology • The side effects Laboratories, Inc., 229 Cleveland ficiency anemia. commonly encountered in iron Avenue, Harrison, New Jersey.

JOURNAL A.0 A., VOL. 62, MAPCLI 176; 651/173 STREXATE TABLETS wherever the combined effects of , analgesic, and Chemistry • Strexate is a combi- anti-inflammatory actions are de- nation of styramate (2-hydroxy-2- sired. It has been successfully phenylethyl ), salicylam- used in muscular strains and ide, acetophenetidin, and caffeine. sprains, lumbago, whiplash in- juries, bursitis, fibrositis, fibromyo- sitis, myositis, neuritis, osteoarthri- Pharmacodynamics • Styramate tis, Stills disease, rheumatoid spon- is a muscle relaxant that acts only dylitis, synovitis, tenosynovitis, on the polysynaptic pathways of torticollis, and contusions. the ext •apyramidal tract in the central nervous system, influencing Contraindications • Strexate is only motor functions. Salicylamide not recommended for patients has the analgesic and antirheumatic known to be sensitive to salicylates, action of the salicylates and is and should be used with caution promptly absorbed from the gastro- in cases of active peptic ulcer. Pro- intestinal tract. Acetophenetidin longed use is contraindicated in provides non-narcotic analgesia, cases of anemia or of cardiac, pul- and the caffeine component exerts monary, renal, or hepatic disease. a stimulatory effect on the central nervous system. Dosage schedule • The usual dosage of Strexate is 1 or 2 tablets Toxicology • Strexate has been three or four times daily, depend- shown to be virtually free of side ing on the severity of pain and effects, but physicians should al- muscle spasm. ways consider the possibility of occasional gastrointestinal disturb- How supplied • Strexate is avail- ances and drowsiness. Styramate able on prescription only, as plain has been reported to cause vertigo, white tablets in bottles of 50. headache, and urticarial eruptions in a few cases. Manufacturer • The S. E. Mas- sengill Company, Bristol, Tennes- Indications • Strexate is indicated see.

STREXATE 11411Mlitt

-111111 4L 2 " 1.347- 474.64511 317:6-72 ;7 444":". 1 041,Lerawt 00 or i•v 14660 70110"11 Gaels61%

.064ttbottil .0000.0.04104401,144. St441 1.1 ComPAN ,

652/174 SURGICAL PREP SET plastic is now used for the multi- cup tray which contains all the Description • A new disposable necessary items: a septisol-satu- Surgical Prep Set provides a plas- rated lathering sponge, a plastic- tic snap-up razor with two double- coated underpad, large cotton balls, edged blades, which makes the set and a super-absorbent towel. The suitable for both major and minor set is sealed in a plastic overwrap procedures. The two ready-to-use which will also serve as a waste sterile blades extend the comforta- receptacle. ble shaving capacity of the dispos- able razor and thus eliminate skin Manufacturer • Davol Rubber irritations caused by worn and dull Company, Providence, Rhode Is- blades. A reinforced heavy-gauge land.

JOURNAL A.O.A., VOL. 62, MARCH 1963 653/175 PORTABLE UPTAKE SYSTEM tube, fits into a %-inch lead shield in such a way that the taper front Description • An inexpensive portion of the shield acts as a 36- portable system for measuring thy- degree collimator. This angle en- roid uptake of 1 131 has recently ables the crystal to "see" the whole been developed. The system com- thyroid gland of most patients at prises an efficiently shielded and a distance of 20 cm. from crystal collimated scintillation detector, to skin. The system can handle a with a thallium-activated sodium maximum average counting rate of iodine crystal 1% inches in diam- about 300,000/minute, and a re- eter and 1 inch long, a table top solving time of 30 microseconds. probe holder, a transistorized five- Stability of the high-voltage sup- decade scaler with coarse and fine ply for an 3-hour period is 0.1 per voltage controls, and a timer that cent; accuracy of the preset timer can he preset for any interval be- is within 0.1 seconds. tween 1 second and 1 hour. The scintillation detector, mounted in- Manufacturer • Picker X-Ray tegrally with the photo-multiplier Corporation, White Plains, N.Y.

•54/176 ORAGRAFIN® the calcium salt is used. Contrast ney impairment. Although gastro- density is excellent even in obese intestinal disorders which interfere Chemistry • Oragrafin, an oral patients. Bile function may read- with absorption are not absolute radiopaque medium for cholangi- ily be observed, and nonopaque contraindications, Oragrafin studies ography and cholecystography, is stones as well as radiodense calculi in such cases are likely to produce a brand of ipodate, which has the and papillomata may be visualized. unsatisfactory results. formula 3- ( dimethylamino-methy- Thus Oragrafin provides a reliable lene-amino)-2,4,6-triiodophenylpro- means of diagnostic study in cases Dosage schedule • For rapid pionic acid. Oragrafin Sodium in which intravenous radiography radiographic examinations, Ora- Capsules and Oragrafin Calcium is hazardous. grafin Calcium may be given to Granules provide the sodium and unprepared patients on the morn- calcium salts respectively. The Toxicology • Side effects that ing of roentgenography. For rou- iodine content of ipodate calcium sometimes occur include mild and tine oral cholecystography, either is 61.7 per cent; that of ipodate transient nausea, vomiting, or diar- salt may be administered the night sodium, 61.4 per cent. Ipodate rhea, headache, dysuria, signs of before, and a further dose of Ora- sodium is highly soluble in water, hypersensitivity, and abdominal grafin Calcium on the morning of while ipodate calcium is practically pains. The incidence can be re- the examination if cholangiography insoluble in water. duced by restricting the dosage to is also desired. Capsules should he 3 grams and by using only Ora- taken with as little water as possi- ble, and may be swallowed in Pharmacodynamics • Both Ora- grafin Calcium Granules for pa- rapid succession or slowly over a grafin salts are rapidly absorbed tients susceptible to gastrointestinal half-hour or more. Granules should from the gastrointestinal tract, the disturbance. he stirred in lukewarm water and calcium salt appearing in the ducts swallowed immediately. as early as 30 minutes after in- Indications • Oragrafin Sodium gestion. Optimal concentration of Capsules and Calcium Granules How supplied • Oragrafin Cal- either salt in the hepatic and biliary are indicated for cholangiography cium Granules are available in ducts usually occurs within 1 to 3 and cholecystography, particularly single-dose packets each supplying hours, and opacification persists for for aged patients, those with car- 3 grams of ipodate calcium dis- about 45 minutes. With careful diovascular disease, or those who persed in flavored sucrose. Ora- timing of the examination and the exhibit sensitivity to the test dose grafin Sodium is available in cap- use of tomograms or laminograms, of an intravenous agent. sule form, providing 0.5 gram of the frequency of good results can ipodate sodium per capsule, in vi- approximate that obtained with Contraindications • Oragrafin is als of 6 capsules and bottles of 100. intravenous agents. In gallbladder contraindicated for persons sensi- studies, diagnostically adequate fill- tive to oral iodine compounds and Manufacturer • E. B. Squibb ing often takes place within 5 hours for those who have combined renal Sons, New York. after ingestion, particularly when and hepatic disease or severe kid-

655/177 JOURNAL A.O.A., VOL. 62, MARCH 1963 LEMMA N"4 METHENOXALONE TAILETS 400 msg.

Aiagistat 110tA70110/‘. M1twA u I ,v

LENETRAN TABLETS TM everyday situations. The effect of tered in medical practice. The drug Lenetran on animal behavior in is also useful as an adjunct in the Chemistry • Lenetran is a brand experimental studies conforms with treatment of premenstrual tension, of , which has the the definition of a tranquilizing dysmenorrhea, alcoholism, meno- formula 5-(o-methoxyphenoxy- agent; the relaxant action does not pause, and psychosomatic disease. methyl)-2-oxazolidinone. Structur- disturb the basic electroencephalo- ally it is a new molecule. Like graphic pattern and does not inter- Contraindications • Lenetran is , Lenetran is related fere with perception or ability to not indicated for the treatment of to but it is not a de- respond to stimuli. psychotic behavior, and probably rivative of either, and it also differs should not be used during preg- structurally from the phenothia- nancy until further study has been zines. Toxicology • Side effects with Lenetran are usually mild and made. No specific contraindications to the use of Lenetran have been Pharmacodynam ics • Lenetran transitory, and may include dizzi- reported, however. is rapidly absorbed and almost ness, nausea, drowsiness, headache, completely metabolized. Clinical or rash. No significant clinical Dosage schedule studies have shown this agent to toxicity has been observed to date; • The recom- mended dosage for adult patient is be effective against anxiety and nevertheless, routine hemograms one tablet four times daily, with tension, without inducing euphoria and differential counts are advisa- or detachment. Therapeutic re- ble, particularly in cases of drug- minimum maintenance dosage be- ing sponse is prompt and is maintained induced anemia. Safe use of this established as soon as possible. throughout therapy without dis- drug during pregnancy has not How supplied • Lenetran Tablets, cernible fluctuations. Neither been established. 400 mg., are available in bottles of habituation nor withdrawal symp- 50 and 500. toms have been reported. Patients Indications • The primary indica- receiving the recommended dose tions for Lenetran are the common Manufacturer • Lakeside Labora- generally demonstrate normal psychological problems of adapta- tories, Inc., Milwaukee 1, Wiscon- awareness and responsiveness to tion as they are generally encoun- sin.

656/178